This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Unstable Angina Therapeutics Market

Market Insights on Unstable Angina Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Unstable Angina Therapeutics Market Forecast by Treatment, End User & Region | Forecast 2023 to 2033

Unstable Angina Therapeutics Market Snapshot (2023 to 2033)

Valued at US$ 3.86 billion in 2022, the market for unstable angina therapeutics is foreseen to increase to US$ 4.05 billion in FY 2023, representing a Y-o-Y increase of 4.9%. Over the forecast period ranging from 2023 to 2033, the market is anticipated to gain traction at a CAGR of 5%, reaching an industry value of US$ 6.6 billion. According to a Cleveland Clinic report, approximately 200,000 Americans suffer from unstable angina every year. Unstable angina is more prevalent among older people, men, and those who smoke, have high blood sugar levels, or have hypertension.

The primary factors driving the market growth are an augmentation in the number of patients being treated for unstable angina and the authorization of new therapeutics with high safety and effectiveness. Rivaroxaban, varespladib, and otamixaban are a few instances of new therapeutics that are presently in the late phases of clinical progression. If authorized, these products are predicted to be advertised at high prices. Nevertheless, a low adoption rate of therapeutic strategies in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market.

If there is an artery obstruction or shrinking, the practitioner may suggest invasive surgery like angioplasty, and in severe instances, cardiac bypass surgery. The market for unstable angina therapeutics has tremendous growth potential, owing primarily to a rise in the number of people suffering from cardiac ailments, increased tobacco use, poor dietary habits, and lifestyle changes. Therefore, increasing awareness about lifestyle changes is also predicted to boost market growth.

As per one 2020 article, roughly 18 million individuals in the United States suffer from unstable angina. Furthermore, the Americas are expected to represent the majority of global percutaneous coronary interventions. As percutaneous coronary intervention (PCI) is growing more prevalent in the United States and Canada, that region is expected to be the leader in the unstable angina therapeutics industry in the forthcoming years. Because of the increasing prevalence of cardiovascular diseases, enhanced medical facilities, and increasing disposable income, Asia-Pacific is estimated to accelerate at the fastest pace. The Middle East and Africa market share are predicted to grow due to the significant recurrence of therapeutic intervention in Kuwait, Saudi Arabia, and the UAE.

Aspects such as the soaring prevalence of numerous cardiovascular disorders including Coronary Heart Disease (CHD), myocardial infarction, and strokes, in addition to the growing requirement for minimally invasive surgeries, are contributing to the expansion of the coronary artery bypass graft (CABG) surgery segment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are growing in popularity due to variables such as the growing incidence of pain around the world, as well as an enhancement in the worldwide aging populations. Because of the high adoption rate of effective therapies for unstable angina patients, the hospital segment held the largest market share among end-user segments.

Leading healthcare practitioners in the market are employing a variety of therapeutic and combat strategies. These include a variety of measures such as pipeline research to develop effective drug applicants, in-house therapy sessions, and collaboration with healthcare technology providers to establish advanced therapeutics infrastructures.

Data Points

Key Statistics

Expected Market Value (2023)

US$ 4.05 billion

Anticipated Forecast Value (2033)

US$ 6.6 billion

Projected Growth Rate (2023 to 2033)

5% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

Unstable Angina Therapeutics Historical Analysis 2018 to 2022 vs. Future Prospects 2023 to 2033

According to Future Market Insights, unstable angina therapeutics experienced a substantial boost from 2018 to 2022, with a CAGR of 4%. COVID-19 had become a significant public health concern in the historical period. In the past, unsuitable cautions against the usage of NSAID stimulants for COVID-19 patients with a higher likelihood of adverse impacts have been imposed. This caused widespread consternation among patient populations and the healthcare sector. As a result, COVID-19 had a significant impact on the consumption and prescription of various drugs for unstable angina in the global market.

Increasing medical prices will raise the economic strain on uninsured patients over the projected timeframe, causing individuals to migrate to developing countries where surgery costs less. This, in turn, is increasing the need for medical tourism in evolving countries. Among the main determinants predicted to propel the market in emerging economies over the forecast period are the presence of advantages like improved healthcare, lower surgical costs, and superior hospitality.

Prominent Drivers Influencing Market Growth of Unstable Angina Therapeutics

Global Geriatric Population Growth to steer Market Growth

As a result, the growing elderly population around the world is predicted to propel market growth. Based on an Administration on Aging (AoA) report, the number of people aged 65 and older in the United States was about 54.1 million in 2019, accounting for more than 16% of the total population.

There were approximately 30 million women and approximately 24.1 million men among them. By 2040, this population is predicted to account for 21.6% of the total in the United States. As a result, the growing geriatric population is predicted to drive the expansion of the unstable angina therapeutics market in the coming years.

Drugs Authorization by government drives Market Growth

The increasing number of medications approved by government agencies is expected to drive the growth of the unstable angina therapeutics market in the coming decades. Clopidogrel, for instance, is FDA-approved for the medical treatment of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI).

Clopidogrel, when combined with aspirin, has historically been demonstrated to lower the probability of death, reoccurring heart attacks, or stroke in patient populations with unstable angina or a less severe cardiac attack.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Low Adoption Rate of Treatment and High Costs to Hinder Market Growth

Nevertheless, a low adoption rate of new treatments in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market. Other attributes like patent expirations and the exorbitant prices of drug development may also impede market growth. For instance, a coronary artery bypass graft surgery costs an average of $54,000 - $148,400 in the United States.

Region-Wise Insights

What Makes North America the Largest Market for Unstable Angina Therapeutics?

Advanced Surgeries and Treatments Options drive the Regional Market Growth

Owing to the evolving guidelines related to patient treatment and management, North America is anticipated to dominate the unstable angina therapeutics market over the coming years. The occurrence of unstable angina is escalating in the United States, with nearly 1 million hospitalized patients having a primary diagnosis of unstable angina every year. As a result, this aspect is anticipated to contribute to industry growth.

Furthermore, North America is predicted to control the whole coronary artery bypass graft surgery market across the forthcoming years, driving future growth even further. For instance, as per data released by the Centers for Disease Control and Prevention in July 2022, 20.1 million Americans aged 20 and adults over the age were impacted by coronary heart disease in 2020. North America accounted for 45% market share in 2022.

Why is Europe Considered a Lucrative Region for the Unstable Angina Therapeutics Market?

Europe is the world's 2nd largest market for Unstable Angina Therapeutics

According to a recent article in Academic Group, Europe is the second largest industry for unstable angina therapeutics. Aspects including the accessibility of research grants, a burgeoning obese and patient citizenry, and the involvement of advanced economies like France, Italy, and Germany in the region all provide favorable backdrops for regional market expansion.

Unstable angina causes over 115,000 acute hospitalizations in the UK each year (200 per 100,000 population), with a substantial male predominance. In Europe, hospitalization rates for unstable angina outnumber those for ST-elevation myocardial infarction1. Before the introduction of modern treatment modalities, 15% of patients with unstable angina proceeded to a severe myocardial infarction, with total in-hospital mortality reaching 5%. Thus these factors are expected to propel the regional market.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

By End-User, Which Segment is Projected to Lead the Market?

Hospital Segment is Estimated to Hold the Largest Share

The hospital segment led the market in 2022, accounting for 46% of total revenue. Hospitals are commonly considered primary healthcare systems, and the patient population's preference for hospitals for the evaluation and treatment of chronic disorders is fuelling segment growth. Furthermore, the same segment is expected to grow at the fastest rate between 2023 and 2033.

By Treatment, Which Segment is Projected to Lead the Market?

Beta Blockers Segment is Estimated to Hold the Largest Share

The beta blockers segment is anticipated to expand at a CAGR of 4.4% during the projected timeline. Because of technological developments, massive expenditure, higher incidence and occurrence of cardiovascular diseases, and an aging population, the popularity of beta blockers has risen exponentially. Furthermore, the segment will benefit from a rising patient population and a lack of adequate treatment.

The Start-up Ecosystem: How Key Players are making Unstable Angina Therapeutics Easier?

Various start-ups are launching advanced treatment procedures and drugs to drive market growth. For instance,

  • Laura Niklason, MD, Ph. established Humacyte, Inc in 2004. Humacyte, Company revealed outcomes from the first clinical study of Humacyte's small-diameter (3.5mm) Human Acellular Vessel (HAV) in coronary artery bypass grafting (CABG) at Advanced Therapeutic Approaches Week in January 2022.

Market Competition

Key players in the Unstable Angina Therapeutics market are Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark Kinetics, CDH Fine Chemical. Some of the latest developments are below,

  • In patients with an initial MI or unstable angina pectoris, Bayer Healthcare has launched aspirin, which is prescribed to reduce the combined risk of death and previous MI or unstable angina pectoris.
  • Praluent® (alirocumab) was approved by the FDA in April 2019 to prevent heart attacks, strokes, and unstable angina that requires hospitalization. Praluent treatment was found to be effective in patients who were already obtaining other lipid-lowering treatments, such as sufficiently acceptable statins.

Report Scope

Report Attribute

Details

Expected Market Value (2023)

US$ 4.05 billion

Anticipated Forecast Value (2033)

US$ 6.6 billion

Projected Growth Rate (2023 to 2033)

5% CAGR

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Treatment
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Indonesia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Bayer AG
  • Sanofi S.A
  • Anthera Pharmaceuticals
  • Ablynx
  • Saphnix Lifesciences
  • Copperhead Chemical
  • Medtronic
  • Enomark
  • Kinetics
  • CDH Fine Chemical

Customization

Available Upon Request

Key Segments Profiled in the Unstable Angina Therapeutics Industry Survey

By Treatment:

  • Percutaneous Coronary Intervention (PCI)
  • Coronary Artery Bypass Graft Surgery
  • Supplemental Oxygen Therapy
  • Drug Class
    • NSAIDs
    • Vasodilators
    • Platelet Aggregation Inhibitors
    • Anticoagulants
    • Beta-blockers

By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

FMI projects the global Unstable Angina Therapeutics market to expand at a 5% value CAGR by 2033.

The global Unstable Angina Therapeutics market is estimated at a market value of US$ 4.05 billion.

The global Unstable Angina Therapeutics market is expected to garner a market value of US$ 6.6 billion.

FMI has projected North America to be one of the key regions for the Unstable Angina Therapeutics market.

Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark, Kinetics, and CDH Fine Chemical.

Table of Content

1. Executive Summary | Unstable Angina Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Percutaneous Coronary Intervention (PCI)

        5.3.2. Coronary Artery Bypass Graft Surgery

        5.3.3. Supplemental Oxygen Therapy

        5.3.4. Drug Class

            5.3.4.1. NSAIDs

            5.3.4.2. Vasodilators

            5.3.4.3. Platelet Aggregation Inhibitors

            5.3.4.4. Anticoagulants

            5.3.4.5. Beta-blockers

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Specialty Clinics

        6.3.3. Ambulatory Surgical Centres

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States

            8.2.1.2. Canada

        8.2.2. By Treatment

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By End User

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Treatment

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By End User

    11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of Middle East and Africa

        12.2.2. By Treatment

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By End User

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. United States

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Treatment

            13.1.2.2. By End User

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Treatment

            13.2.2.2. By End User

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Treatment

            13.3.2.2. By End User

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Treatment

            13.4.2.2. By End User

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Treatment

            13.5.2.2. By End User

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Treatment

            13.6.2.2. By End User

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Treatment

            13.7.2.2. By End User

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Treatment

            13.8.2.2. By End User

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Treatment

            13.9.2.2. By End User

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Treatment

            13.10.2.2. By End User

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Treatment

            13.11.2.2. By End User

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Treatment

            13.12.2.2. By End User

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Treatment

            13.13.2.2. By End User

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Treatment

            13.14.2.2. By End User

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Treatment

            13.15.2.2. By End User

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Treatment

            13.16.2.2. By End User

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Treatment

            13.17.2.2. By End User

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Treatment

            13.18.2.2. By End User

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Treatment

            13.19.2.2. By End User

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Treatment

            13.20.2.2. By End User

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Treatment

        14.3.3. By End User

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Bayer AG

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Sanofi S.A

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Anthera Pharmaceuticals Inc.

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Ablynx

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Saphnix Lifesciences

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Copperhead Chemical Company

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Medtronic Plc.

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Enomark

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Cytokinetics Inc.

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. CDH Fine Chemical

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology
Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 89: MEA Market Attractiveness by End User, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Prinzmetal Angina Therapeutics Market

Published : January 2023

Healthcare

Heart Beat Irregularity Detection Device Market

Published : March 2022

Healthcare

Coronary Stents Market

Published : January 2020

Healthcare

Coronary Artery Bypass Grafts Market

Published : March 2022

Google translate

Unstable Angina Therapeutics Market